Abstract
Importance While apathy and affective neuropsychiatric symptoms (NPS) are common in the clinical spectrum of Alzheimer’s disease (AD), their neurobiological correlates remain unclear.
Objective To longitudinally examine plasma markers of neurodegeneration (neurofilament light chain; NfL) and tau pathology (phosphorylated at threonine 181; p-tau181) and their associations with apathy and affective symptoms in individuals with clinical diagnoses of AD dementia and mild cognitive impairment (MCI).
Design, Setting, Participants and Exposure This cohort study used longitudinal data from the Alzheimer Disease Neuroimaging Initiative (ADNI). Individuals with clinical diagnoses of MCI and AD dementia were enrolled in ADNI with serial annual blood samples over a four-year period, which were analyzed for NfL and p-tau181 using ultrasensitive techniques. Study data were accessed between July and September 2024.
Main Outcomes and Measures The presence of neuropsychiatric symptoms was determined using the Neuropsychiatric Interview (NPI). We analyzed the trajectory of plasma NfL and p-tau181 in each NPS using general linear mixed-effects models adjusted for age and sex.
Results There were 790 participants with AD dementia and MCI (mean [SD] age 72.7 [7.6] years; 333 females, 42%) and 417 healthy controls. The most common NPS was depression (n = 428; 54%), followed by irritability (n = 419; 53%), apathy (n = 348; 44%) and anxiety (n = 341; 43%). In the AD dementia and MCI group, apathy and anxiety were associated with higher levels of both NfL and p-tau181 after controlling for cognitive and functional decline. Moreover, apathy was associated with higher rate of NfL increase longitudinally. Depression at baseline was initially associated with higher NfL and p-tau181 levels, but this did not remain significant in the sensitivity analyses.
Conclusion and Relevance This study found that in individuals with clinical AD, apathy and anxiety are associated greater tau and neurodegenerative burden. Furthermore, those with apathy had a higher rate of NfL increase, which suggests an accelerated neurodegenerative process. These findings highlight that these symptoms be indicative of AD pathology severity and have implications for potential treatments which target tau pathology.
Key Points Question: Do apathy and affective neuropsychiatric symptoms correlate with the rate of tau pathology and neurodegeneration, as measured by plasma phosphorylated-tau181 (p-tau181) and neurofilament light chain protein (NfL), in individuals across the clinical spectrum of Alzheimer’s disease (AD)?
Findings: In a longitudinal study of 790 patients with mild cognitive impairment (MCI) and AD dementia, serial measurements of plasma p-tau181 and NfL were collected annually over four years. P-tau181 and NfL levels were elevated in those with apathy or anxiety compared to those without. The rate of NfL increase, an indicator of neurodegeneration, was significantly higher in those with apathy.
Meaning: The presence of anxiety and apathy was associated with elevated biomarkers of neurodegeneration in MCI and AD dementia. Notably, apathy was linked to a faster rate of NfL increase, suggesting an accelerated neurodegenerative process.
Competing Interest Statement
HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. SL has received honorarium from Lundbeck and Otsuka. MH has served as a consultant and at advisory boards for Boehringer-Ingelheim, Cortexa, Eli Lilly, Janssen, Lundbeck, Novartis, Otsuka, Orion, Servier and Takeda. He has received research support from Alto Neuroscience, Boehringer-Ingelheim, Douglas, Janssen, and Lyndra, PBM has received honoraria from Janssen (Australia) for lectures and advisory board membership The remaining authors declare no conflict of interests.
Funding Statement
Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging (National Institutes of Health Grant U19AG024904). The grantee organization is the Northern California Institute for Research and Education. In the past, ADNI has also received funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health (FNIH) including generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. MK is supported by the Nick Christopher PhD scholarship and the Research Training Program Scholarship from the Department of Psychiatry, University of Melbourne with contributions from the Australian Commonwealth Government, and the Ramsay Hospital Research Foundation. A.F.S is primarily funded by the Swedish federal government under the ALF agreement (ALF ALF 2022 YF 0017) The Fromma foundation and The Ake Wiberg foundation. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Unions Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Unions Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Ronstroms Stiftelse, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2022-0270), the European Unions Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjarnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Ronstroms Stiftelse, Stockholm, Sweden. PBM is supported by an Australian NHMRC Investigator Grant (1177991), Lansdowne Foundation and Good Talk charity
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the Alzheimer Disease Neuroimaging Initiative (ADNI) study was obtained from the medical ethics committees of all participating institutions, and written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
↵^ CB Malpas and D Velakoulis are joint senior authors
deratne{at}unimelb.edu.au, Samantha.loi{at}unimelb.edu.au, christa.dang{at}unimelb.edu.au, alexander.santillo{at}med.lu.se, henrik.zetterberg{at}gu.se, kaj.blennow{at}neuro.gu.se, Phil.mitchell{at}unsw.edu.au, mhopwood{at}unimelb.edu.au, charles.malpas{at}unimelb.edu.au, Dennis.Velakoulis{at}mh.org.au
Data Availability
All data produced are available online at https://adni.loni.usc.edu/
